Virafin News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Virafin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Virafin Today - Breaking & Trending Today
NEW DELHI: Drug Controller General Of India (DCGI) has granted restricted emergency use approval to Zydus Cadila s Virafin for treating patients showing moderate Covid-19 symptoms, the department of biotechnology said on Saturday. Virafin is a pegylated interferon alpha-2b(PegIFN), which when subcutaneously injected to the patient in the early stages of infection, results in their faster recovery, it said. The studies confirmed the safety, tolerability and efficacy of Virafin. The studies also reported that Viarfin reduces viral load and aid in managing the disease in a better way, such as reduction in the need for supplemental oxygen, thereby reducing the respiratory tension caused due to low oxygen levels, the DBT said. ....
Emergency Use Approved for Virafin Against COVID-19 by Angela Mohan on April 24, 2021 at 7:10 PM Virafin received emergency use approval for treating moderate COVID-19 infection in adults. The single dose subcutaneous regimen of the anti-viral drug reduced the need for supplemental oxygen, indicating that it was able to control respiratory distress and failure one of the major challenges in treating COVID-19, according to results of a multicentric trial conducted in 20-25 centres across India. About 91.15 per cent of patients treated with the drug were RT-PCR negative by day seven, the company said in a statement. The drug has also shown efficacy against other viral infections, it added. It will be available on the prescription of a medical specialist for use in hospital/institutional setup. ....
Zydus Virafin gets emergency use approval for treating moderate COVID-19 cases ANI | Updated: Apr 23, 2021 16:04 IST New Delhi [India], April 23 (ANI): The Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila s Pegylated Interferon alpha-2b, Virafin for treating moderate COVID-19 infection in adults. A release by Cadila Health said, The drug has also shown efficacy against other viral infections. Speaking on the development, Dr Sharvil Patel, Managing Director, Cadila Healthcare Limited said: The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management. It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19. ....